338
Views
19
CrossRef citations to date
0
Altmetric
Research Article

Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter's syndrome: 36 months follow-up

, , &
Pages 524-527 | Received 07 Apr 2013, Accepted 01 Jun 2013, Published online: 10 Jul 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (8)

Gülseren Tuncay, Ebru Damadoglu, Melek Cihanbeylerden, Ozge Can Bostan, Hazal Kayıkcı, Serdar Özer, Gül Karakaya & Ali Fuat Kalyoncu. (2023) Comparison of the clinical outcomes of patients with NSAID-exacerbated respiratory disease receiving aspirin or biologicals. Journal of Asthma 60:10, pages 1885-1894.
Read now
Olga Branicka, Edyta Jura-Szołtys, Barbara Rogala & Joanna Glück. (2021) sCD48 is elevated in non-allergic but not in allergic persistent rhinitis. Immunopharmacology and Immunotoxicology 43:6, pages 724-730.
Read now
Arzu Didem Yalcin & Ata Nevzat Yalcin. (2021) Future perspective: biologic agents in patients with severe COVID-19. Immunopharmacology and Immunotoxicology 43:1, pages 1-7.
Read now
Arzu Didem Yalcin & Ata Nevzat Yalcin. (2020) A case of asthma with Behcet’s disease: successful treatment with omalizumab and its effects on recurrent aphthous lesions. Immunopharmacology and Immunotoxicology 42:4, pages 379-382.
Read now
Howraman Meteran, Hanieh Meteran, Celeste Porsbjerg & Vibeke Backer. (2017) Novel monoclonal treatments in severe asthma. Journal of Asthma 54:10, pages 991-1011.
Read now
John W Steinke & Jeff M Wilson. (2016) Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances. Journal of Asthma and Allergy 9, pages 37-43.
Read now
Seda Tural Onur, Arzu Didem Yalcin, Betul Celik & Saadet Gumuslu. (2015) Evaluation of d-dimer, CXCL8, homocysteine, eosinophil cationic peptide, 25(OH)-vitamin D and immunomodulatory OX-2 levels in allergic patients. Journal of Asthma 52:2, pages 123-127.
Read now
Arzu Didem Yalcin, Aykut Cilli, Atil Bisgin, Ludwig G Strauss & Felix Herth. (2013) Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels. Expert Opinion on Biological Therapy 13:9, pages 1335-1341.
Read now

Articles from other publishers (11)

Jody Tversky, Andrew P. Lane & Antoine Azar. (2021) Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double‐blind placebo‐controlled trial. Clinical & Experimental Allergy 51:6, pages 836-844.
Crossref
Arzu D. Yalcin & Rusen Uzun. (2019) Anti-IgE Significantly Changes Circulating Interleukin-25, Vitamin-D and Interleukin-33 Levels in Patients with Allergic Asthma. Current Pharmaceutical Design 25:35, pages 3784-3795.
Crossref
Priya Sakthivel, Angele Breithaupt, Marcus Gereke, David A. Copland, Christian Schulz, Achim D. Gruber, Andrew D. Dick, Jens Schreiber & Dunja Bruder. (2016) Soluble CD200 Correlates With Interleukin-6 Levels in Sera of COPD Patients: Potential Implication of the CD200/CD200R Axis in the Disease Course. Lung 195:1, pages 59-68.
Crossref
Jaromír Bystroň & Beata Hutyrová. (2016) Evaluation of efficacy of anti-IgE monoclonal antibody treatment not only in severe allergic asthma. Klinická farmakologie a farmacie 30:4, pages 14-18.
Crossref
Karl-Christian Bergmann, Torsten Zuberbier & Martin K. Church. (2015) Omalizumab in the treatment of aspirin-exacerbated respiratory disease. The Journal of Allergy and Clinical Immunology: In Practice 3:3, pages 459-460.
Crossref
Arzu Didem Yalcin. (2015) Advances in Anti-IgE Therapy. BioMed Research International 2015, pages 1-11.
Crossref
AD Yalcin. (2014) ANTI-Ige: An Overview. Global Journal of Allergy, pages 003-012.
Crossref
Marc Humbert, William Busse, Nicola A. Hanania, Philip J. Lowe, Janice Canvin, Veit J. Erpenbeck & Stephen Holgate. (2014) Omalizumab in Asthma: An Update on Recent Developments. The Journal of Allergy and Clinical Immunology: In Practice 2:5, pages 525-536.e1.
Crossref
Saadet Gumuslu. (2014) Evaluation of soluble CD200 levels in type 2 diabetic foot and nephropathic patients: Association with disease activity. Medical Science Monitor 20, pages 1078-1081.
Crossref
Arzu Didem Yalcin. (2014) An Overview of the Effects of anti-IgE Therapies. Medical Science Monitor 20, pages 1691-1699.
Crossref
Erkan Alpsoy. (2013) There might be a role for CD200 in the pathogenesis of autoimmune and inflammatory skin disorders. Medical Science Monitor 19, pages 888-891.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.